CUE BIOPHARMA INC (CUE)
US22978P1066 - Common Stock
| 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | 2019 (2019-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash | N/A | N/A | N/A | N/A | N/A | |||
| Cash Equivalents | 48.51M | 51.61M | 64.37M | 74.87M | 44.29M | |||
| Marketable Securities | 0.00 | 24.67M | 0.00 | 10.00M | 15.12M | |||
| Receivables | 1.70M | 60.00K | 3.14M | 1.42M | 750.00K | |||
| Other Current Assets | 1.24M | 840.00K | 950.00K | 1.24M | 860.00K | |||
| Total Current Assets | 51.45M | 77.19M | 68.47M | 87.53M | 61.02M | |||
| Non-Current Assets | ||||||||
| PPE Net | 7.12M | 10.70M | 11.92M | 8.88M | 7.18M | |||
| Intangibles | N/A | N/A | N/A | N/A | N/A | |||
| Other Non-Current Assets | 2.96M | 3.39M | 3.01M | 3.12M | 3.40M | |||
| Total Non-Current Assets | 10.08M | 14.09M | 14.93M | 12.00M | 10.59M | |||
| TOTAL ASSETS | 61.53M | 91.28M | 83.40M | 99.53M | 71.61M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Current Portion Of LT Debt. | 3.96M | 1.96M | N/A | N/A | N/A | |||
| Accrued Expenses | 5.93M | 5.82M | 7.29M | 7.07M | 6.41M | |||
| Accounts Payable | 3.50M | 2.73M | 2.59M | 2.07M | 880.00K | |||
| Other Current Liabilities | 3.69M | 1.04M | 2.91M | 7.18M | 4.37M | |||
| Total Current Liabilities | 17.08M | 11.55M | 12.79M | 16.32M | 11.66M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 4.20M | 8.03M | 0.00 | 0.00 | 0.00 | |||
| Other Non-Current Liabilities | 3.16M | 6.02M | 5.12M | 4.31M | 5.37M | |||
| Total Non-Current Liabilities | 7.36M | 14.05M | 5.12M | 4.30M | 5.36M | |||
| TOTAL LIABILITIES | 24.45M | 25.60M | 17.91M | 20.62M | 17.02M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -301.19M | -250.46M | -197.45M | -153.29M | -108.50M | |||
| Additional Paid In Capital | 338.23M | 316.19M | 262.91M | 232.16M | 163.07M | |||
| Common Shares | 47.00K | 40.00K | 30.00K | 30.00K | 30.00K | |||
| Other Shareholders' Equity | 0.00 | -100.00K | 0.00 | 10.00K | -10.00K | |||
| Shares Outstanding | 47.22M | 43.04M | 32.20M | 30.35M | 26.56M | |||
| Tangible Book Value per Share | 0.79 | 1.53 | 2.03 | 2.60 | 2.06 | |||
| Total Shareholders' Equity | 37.09M | 65.68M | 65.49M | 78.91M | 54.58M | |||
| TOTAL LIABILITIES AND EQUITY | 61.53M | 91.28M | 83.40M | 99.53M | 71.61M | |||
| Statistics | ||||||||
| Debt/Equity | 0.11 | 0.12 | N/A | N/A | N/A | |||
| Current Ratio | 3.01 | 6.68 | 5.35 | 5.36 | 5.23 | |||
| Return On Assets (ROA) | -82.45% | -58.07% | -52.95% | -44.99% | -51.25% | |||
| Return On Equity (ROE) | -136.80% | -80.71% | -67.43% | -56.75% | -67.24% | |||
All data in USD